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s it Possible to
everse the Endothelial
ysfunction in Pulmonary
rterial Hypertension?*
obyn Barst, MD, FACC
ew York, New York
ulmonary arterial hypertension (PAH) is a devastating
isease that in its most severe form, idiopathic PAH, leads
o progressive right heart failure and death within 2 to 3
ears after diagnosis (1). Despite significant advances in
herapeutic modalities for PAH during the past decade (2),
he prognosis remains poor. In addition, although studies
ith animal pulmonary hypertension (PH) models and the
athology from lung tissue in PAH patients show pulmo-
ary arteriolar occlusion, the mechanisms for these pulmo-
ary vascular abnormalities remain unclear. Pulmonary va-
oconstriction, pulmonary vascular proliferation, and
emodeling of the pulmonary vessels and thrombosis in situ
See page 1566
ll seem to be contributing factors to the increased pulmo-
ary vascular resistance in PAH. The pulmonary vasocon-
triction is believed to be caused by abnormal expression of
ulmonary vascular smooth muscle calcium channels and
ndothelial dysfunction. Abnormally increased pulmonary
asoconstriction alters cell proliferation, coagulation factors,
rowth factors, and vasoactive mediators. An imbalance in
hese pulmonary vasoactive mediators promotes further
ulmonary vasoconstriction and pulmonary vascular remod-
ling. Patients with PAH have decreased prostacyclin and
itric oxide synthase and increased thromboxane A2 and
ndothelin-1. Furthermore, based on the mutations in the
one morphogenetic protein receptor II gene considered
ausal for patients with familial PAH and some patients
ith idiopathic pulmonary arterial hypertension (IPAH),
he current dogma for the pathobiology of PAH suggests
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From Columbia University, New York, New York. Dr. Barst is a consultant witha
ctelion, Biogen Idec, Encysive, Gilead, INO, Lilly, LungRx, Medtronics, Mon-
oBiotech, Novartis, Pfizer, and United Therapeutics.hat an injury occurring in a genetically predisposed
ndividual initiates the development of the PAH (Fig. 1).
espite the uncertainty of the exact mechanisms causing
he pulmonary arteriolar obstruction, endothelial cell
poptosis could initiate microvascular degeneration or
esult in proliferative apoptosis-resistant endothelial
ells. Thus, regeneration of the pulmonary vascular bed
ould be a novel therapeutic approach for reversal of the
ulmonary vascular disease in patients with PAH.
One of the most interesting breakthroughs in vascular
iology in recent years has been the discovery of endothelial
rogenitor cells (EPCs) (3). These angiogenic cells mobilize
rom the bone marrow in response to injury. With proper-
ies of embryonal angioblasts, EPCs are thought to have
roliferative potential and may be important in vascular
egeneration. The EPCs therefore may function to replace
nd/or restore damaged endothelial cells. In the field of
ardiovascular disease, circulating EPCs are considered
rotective and low levels of EPCs predict poor outcome.
ased on these observations, EPCs have been postulated to
ontribute to the maintenance of the systemic vasculature
nd the remodeling that accompanies new vessel growth
fter ischemia. It therefore would seem reasonable that if
athological processes that damage the systemic vascular
ndothelium result in endothelial cell detachment from
echanical injury abnormalities, EPCs as a therapeutic
odality could be efficacious in restoring vascular endothe-
ial function.
Several groups have examined whether regeneration of
ulmonary microvessels in experimental PH models is
ossible. In the monocrotaline PH model, EPC therapy
esults in less pulmonary vascular disease, which could in
art be caused by repair and regeneration of the pulmonary
icrovascular endothelium, consistent with the hypothesis
hat endothelial damage resulting in endothelial dysfunction
nd proliferation contributes to pulmonary vascular disease.
hether the decreased pulmonary vascular damage induced
y EPC therapy in the monocrotaline PH model is caused
y endothelial repair directly or indirectly by release of
aracrine signals is unknown. Regardless, these studies
upport the premise that pulmonary microvascular degen-
ration at the precapillary level may play an important role
n the development of PAH. These data also support
ulmonary endothelial cells as a therapeutic target for the
reatment of PAH. Exploring this hypothesis (i.e., that
mpairment of pulmonary vascular and endothelial ho-
eostasis plays a significant role in the pathobiology of
AH) in the current issue of the Journal, Wang et al. (4)
eport data from a 12-week prospective randomized trial
omparing the effects of intravenously infused autologous
PCs plus conventional therapy with conventional therapy
lone in 31 IPAH patients. Exercise capacity assessed by the
-min walk test was increased in the EPC-treated patients
ompared with the patients in the conventional therapy
lone group. Hemodynamic improvement, i.e., pulmonary
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April 10, 2007:1572–4 Editorial Commentrterial pressure, cardiac output, and pulmonary vascular
esistance, were also improved in the EPC-treated patients
ersus the conventional therapy alone group. No apparent
evere adverse events were reported during the 12-week
tudy. It would be interesting to measure plasma markers
ssessing endothelial function, such as von Willebrand
actor, soluble E-selectin, and/or soluble thrombomodulin,
efore and after treatment with infused autologous EPCs in
AH patients to investigate whether markers of endothelial
unction improve, and if so, whether the improvement in
ndothelial function correlates with the clinical and/or
emodynamic improvement.
As we investigate novel therapeutic strategies for improv-
ng PAH treatment, EPCs offer an intriguing approach. In
ddition, the revolution in molecular medicine has gener-
ted enthusiasm for gene therapy as a novel form of drug
elivery that enlists the synthetic machinery of the patient’s
ells to produce a therapeutic agent. Zhao et al. (5) reported
hat treatment with endothelial nitric oxide synthase
eNOS)-transduced EPCs was more effective than treat-
ent with EPCs alone in reversing pulmonary vascular
isease in the rat monocrotaline PH model. The increased
fficacy with the eNOS gene transfer provides further
upport for the role of endothelium-derived nitric oxide in
ulmonary vascular regeneration. Zhao et al. (5) suggest
hat the loss of pulmonary arteriolar continuity at the
recapillary level may be an early event directly contributing
o the increase in pulmonary vascular resistance because of
he loss of vessels in the pulmonary microcirculation. Based
n these animal studies, and the pilot study by Wang et al.
4) in IPAH patients, further investigation is needed to
xplore regenerative cell-based strategies for the treatment
f patients with severe progressive PAH in whom the
rognosis remains poor despite currently available therapies.
It is an exciting time in the history of clinical develop-
ent for PAH therapies. Before 1996, treatment for IPAH
as limited to conventional therapy (i.e., digoxin, diuretics,
Figure 1 Schematic View of the Pathobiology
of Pulmonary Arterial Hypertensionnticoagulation, supplemental oxygen when clinically indi-
1ated, calcium channel blockers in select patients, and lung
r heart-lung transplantation). Intravenous epoprostenol
as then added to the treatment algorithm for PAH as a
alliative bridge to transplantation. Over the past decade,
rostacyclin analogues, selective and nonselective endothe-
in receptor antagonists, and phosphodiesterase type 5
nhibitors have been developed. These drugs increase exer-
ise capacity, improve functional capacity and quality of life,
mprove hemodynamic parameters, and increase survival in
AH. However, exercise capacity remains significantly im-
aired in at least 50% of patients, similar numbers of
atients remain at least at functional class III, patients
ontinue to have frequent hospitalizations for worsening
AH, and pulmonary hemodynamics remain significantly
bnormal. Despite improved survival, survival remains un-
cceptable. We need to look to the future and to study
ombination therapy, early therapy, and other novel patho-
hysiologic targets (e.g., platelet-derived growth factor in-
ibitors, rho-kinase inhibitors, vasoactive intestinal peptide,
HT2-antagonists) and other immunotherapeutic agents,
s we strive to achieve near-normal exercise capacity, func-
ional class I, marked reductions in hospitalizations and
ulmonary artery pressures, and a quality of life and survival
lose to normal.
If EPC therapy can restore endothelial function, this
pproach could conceivably restore imbalances in vasoactive
ediators. Current therapeutic approaches have focused on
ne pathway at a time, (i.e., the prostacyclin pathway, the
itric oxide pathway, or the endothelin pathway). Thera-
eutic approaches integrating these 3 pathways are the basis
or combination therapy. Furthermore, because the patho-
iology of PAH is considered multifactorial with genetic
isk factors, environmental risk factors, and associated con-
itions, it is not unreasonable to suspect that a given
herapeutic approach will not be efficacious for all patients.
tudies evaluating various disease-specific targeted PH
herapies are needed to individualize treatment. Therefore,
t would not be unreasonable that specific gene therapies
ay be found to be more efficacious in specific patients (e.g.,
NOS gene therapy combined with EPCs as a therapeutic
pproach in patients with decreased expression of nitric
xide synthase).
With these recent advances in the understanding of the
echanisms of disease development in PAH as well as in its
reatment, one day, hopefully in the not-too-distant future,
e may be able to prevent and cure this once uniformly fatal
isease. However, one must remain cognizant of risk-
enefit considerations for all treatment options being con-
idered for individual patients.
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